Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Bowen

Showing results (21-30 of 96) with videos related to

Pageof 10
Sort By:
BMC Medical Education|May 13, 2022
Research supervisors' views of barriers and enablers for research projects undertaken by medical students; a mixed methods evaluation of a post-graduate medical degree research project programJoanne Hart, Jonathan Hakim, Rajneesh Kaur, et al.
European Journal of Cancer (Oxford, England : 1990)|September 1, 2015
Survival patterns in teenagers and young adults with cancer in the United Kingdom: Comparisons with younger and older age groupsDan Stark, David Bowen, Elaine Dunwoodie, et al.
Leukemia Research|July 9, 2010
Practical use of azacitidine in higher-risk myelodysplastic syndromes: an expert panel opinionPierre Fenaux, David Bowen, Norbert Gattermann, et al.
Pharmacoeconomics|September 3, 2013
Ruxolitinib for the treatment of myelofibrosis: a NICE single technology appraisalRos Wade, Micah Rose, Aileen Rae Neilson, et al.
Experimental Hematology|April 29, 2008
Analysis of mitochondrial DNA in 104 patients with myelodysplastic syndromesMichael Wulfert, Anna C Küpper, Christoph Tapprich, et al.
Clinical Lymphoma, Myeloma & Leukemia|December 10, 2014
Should patients with high-risk or transformed myelodysplastic syndrome proceed directly to allogeneic transplant without prior cytoreduction by remission-induction chemotherapy or hypomethylating agent therapy?Theo M de Witte, David Bowen, Marie Robin, et al.
Transfusion|June 10, 2022
Multi-national survey of transfusion experiences and preferences of patients with myelodysplastic syndromeAbi Vijenthira, Rebecca Starkman, Yulia Lin, et al.
British Journal of Haematology|April 29, 2020
De-Iron: a phase 2 trial of the activity and safety of Deferasirox administered at early iron loading in patients with transfusion-dependent myelodysplastic syndromesSally Killick, Aimee Jackson, Helen C Coulthard, et al.
The Oncologist|April 20, 2016
The European Medicines Agency Review of Decitabine (Dacogen) for the Treatment of Adult Patients With Acute Myeloid Leukemia: Summary of the Scientific Assessment of the Committee for Medicinal Products for Human UseMaria Nieto, Pierre Demolis, Eliane Béhanzin, et al.
Haematologica|May 4, 2006
Predicting erythroid response to recombinant erythropoietin plus granulocyte colony-stimulating factor therapy following a single subcutaneous bolus in patients with myelodysplasiaDavid Bowen, Ann Hyslop, Norene Keenan, et al.
Pageof 10

Showing results (21-30 of 96) with videos related to

Sort By:
Pageof 10
BMC Medical Education|May 13, 2022
Research supervisors' views of barriers and enablers for research projects undertaken by medical students; a mixed methods evaluation of a post-graduate medical degree research project programJoanne Hart, Jonathan Hakim, Rajneesh Kaur, et al.
European Journal of Cancer (Oxford, England : 1990)|September 1, 2015
Survival patterns in teenagers and young adults with cancer in the United Kingdom: Comparisons with younger and older age groupsDan Stark, David Bowen, Elaine Dunwoodie, et al.
Leukemia Research|July 9, 2010
Practical use of azacitidine in higher-risk myelodysplastic syndromes: an expert panel opinionPierre Fenaux, David Bowen, Norbert Gattermann, et al.
Pharmacoeconomics|September 3, 2013
Ruxolitinib for the treatment of myelofibrosis: a NICE single technology appraisalRos Wade, Micah Rose, Aileen Rae Neilson, et al.
Experimental Hematology|April 29, 2008
Analysis of mitochondrial DNA in 104 patients with myelodysplastic syndromesMichael Wulfert, Anna C Küpper, Christoph Tapprich, et al.
Clinical Lymphoma, Myeloma & Leukemia|December 10, 2014
Should patients with high-risk or transformed myelodysplastic syndrome proceed directly to allogeneic transplant without prior cytoreduction by remission-induction chemotherapy or hypomethylating agent therapy?Theo M de Witte, David Bowen, Marie Robin, et al.
Transfusion|June 10, 2022
Multi-national survey of transfusion experiences and preferences of patients with myelodysplastic syndromeAbi Vijenthira, Rebecca Starkman, Yulia Lin, et al.
British Journal of Haematology|April 29, 2020
De-Iron: a phase 2 trial of the activity and safety of Deferasirox administered at early iron loading in patients with transfusion-dependent myelodysplastic syndromesSally Killick, Aimee Jackson, Helen C Coulthard, et al.
The Oncologist|April 20, 2016
The European Medicines Agency Review of Decitabine (Dacogen) for the Treatment of Adult Patients With Acute Myeloid Leukemia: Summary of the Scientific Assessment of the Committee for Medicinal Products for Human UseMaria Nieto, Pierre Demolis, Eliane Béhanzin, et al.
Haematologica|May 4, 2006
Predicting erythroid response to recombinant erythropoietin plus granulocyte colony-stimulating factor therapy following a single subcutaneous bolus in patients with myelodysplasiaDavid Bowen, Ann Hyslop, Norene Keenan, et al.
Pageof 10